You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 165 No. 12, June 27, 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (33)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Impact of Inadequate Initial Antimicrobial Therapy on Mortality in Infections Due to Extended-Spectrum {beta}-Lactamase–Producing Enterobacteriaceae

Variability by Site of Infection

Emily P. Hyle, BS; Adam D. Lipworth, BS; Theoklis E. Zaoutis, MD; Irving Nachamkin, DrPH, MPH; Warren B. Bilker, PhD; Ebbing Lautenbach, MD, MPH, MSCE

Arch Intern Med. 2005;165:1375-1380.

Background  Infections due to extended-spectrum {beta}-lactamase–producing Escherichia coli and Klebsiella species (ESBL-EK) have increased markedly in recent years. Risk factors for mortality among ESBL-EK infections have not been studied.

Methods  This retrospective cohort study was conducted in a 625-bed tertiary care medical center and a 344-bed urban community hospital to determine whether inadequate initial antimicrobial therapy (IIAT) (>48 hours between the time a culture was obtained and initiation of an agent to which the infecting organism was susceptible) is associated with mortality in ESBL-EK infections. All hospitalized patients with an ESBL-EK infection between June 1, 1997, and December 31, 2002, were eligible for inclusion. Subsequently, we conducted a nested case-control study to identify risk factors for IIAT.

Results  Of 187 subjects, 32 (17.1%) died while in the hospital. Clinical site of infection was a significant effect modifier in the association between IIAT and mortality. The presence of IIAT was an independent risk factor for mortality, but only for nonurinary ESBL-EK infections (adjusted odds ratio [95% confidence interval], 10.04 [1.90-52.96]). Independent risk factors for IIAT were (1) infection with a multidrug-resistant ESBL-EK (ie, resistant to sulfamethoxazole-trimethoprim, aminoglycosides, and quinolones) (14.58 [1.91-111.36]) and (2) health care–acquired ESBL-EK infection (4.32 [1.49-12.54]).

Conclusions  Inadequate initial antimicrobial therapy is an independent risk factor for mortality in ESBL-EK infections, but only among nonurinary infections. Multidrug resistance was a strong risk factor for IIAT.


Author Affiliations: Center for Clinical Epidemiology and Biostatistics (Ms Hyle, Mr Lipworth, and Drs Zaoutis, Bilker, and Lautenbach), Center for Education and Research on Therapeutics (Ms Hyle, Mr Lipworth, and Drs Zaoutis, Bilker, and Lautenbach), Departments of Pathology and Laboratory Medicine (Dr Nachamkin) and Biostatistics and Epidemiology (Drs Bilker and Lautenbach), and Division of Infectious Diseases, Department of Medicine (Dr Lautenbach), University of Pennsylvania School of Medicine, Philadelphia; and Division of Infectious Diseases, Department of Medicine, The Children’s Hospital of Philadelphia (Dr Zaoutis).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Current Perspectives on Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli
Wright and Eiland
Journal of Pharmacy Practice 2008;21:338-345.
ABSTRACT  

Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy
Tumbarello et al.
Antimicrob. Agents Chemother. 2008;52:3244-3252.
ABSTRACT | FULL TEXT  

Delay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe Neutropenia
Lin et al.
Antimicrob. Agents Chemother. 2008;52:3188-3194.
ABSTRACT | FULL TEXT  

Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes
Cesaro et al.
J Antimicrob Chemother 2008;61:1007-1015.
ABSTRACT | FULL TEXT  

Resistant gram-negative bacilli: A neglected healthcare crisis?
Lautenbach and Polk
Am J Health Syst Pharm 2007;64:S3-S21.
ABSTRACT | FULL TEXT  

Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia
Peralta et al.
J Antimicrob Chemother 2007;60:855-863.
ABSTRACT | FULL TEXT  

The zeitgeist of resistance
Livermore
J Antimicrob Chemother 2007;60:i59-i61.
ABSTRACT | FULL TEXT  

Failure To Control an Outbreak of qnrA1-Positive Multidrug-Resistant Enterobacter cloacae Infection despite Adequate Implementation of Recommended Infection Control Measures
Paauw et al.
J. Clin. Microbiol. 2007;45:1420-1425.
ABSTRACT | FULL TEXT  

Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England
Potz et al.
J Antimicrob Chemother 2006;58:320-326.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.